Aveo Pharmaceuticals Inc. (NYSE: AVEO) will present results from the Phase 1 portion of the Phase 1/2 TiNivo study at the 16th International Kidney Cancer Symposium. The stock price lost 39 cents to close at $3.05.
Aveo Pharmaceuticals to present data
October 17, 2017 at 18:55 PM EDT
